

# CITATION REPORT

List of articles citing

**Chronic endothelin receptor antagonism preserves coronary endothelial function in experimental hypercholesterolemia**

**DOI: 10.1161/01.cir.99.13.1747**  
**Circulation, 1999, 99, 1747-52.**

**Source:** <https://exaly.com/paper-pdf/30145197/citation-report.pdf>

**Version:** 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
101	Endothelin receptor antagonists. Promising new agents in the management of cardiovascular disorders. <b>1999</b> , 2, 1-12		7
100	Current World Literature. <b>2000</b> , 11, 529-547		
99	Increased coronary effects of stimulation of endothelin-B receptor in experimental hypercholesterolemia. <b>2000</b> , 11, 585-92		4
98	Endothelial dysfunction and atherosclerosis: endothelin receptor antagonists as novel therapeutics. <b>2000</b> , 2, 84-91		38
97	Endothelial dysfunction in hypercholesterolemia: mechanisms, pathophysiological importance, and therapeutic interventions. <b>2000</b> , 26, 529-37		97
96	Vascular extracellular superoxide dismutase activity in patients with coronary artery disease: relation to endothelium-dependent vasodilation. <i>Circulation</i> , <b>2000</b> , 101, 2264-70	16.7	219
95	Minimally invasive evaluation of coronary microvascular function by electron beam computed tomography. <i>Circulation</i> , <b>2000</b> , 102, 2411-6	16.7	52
94	Increased activity of endogenous endothelin in patients with hypercholesterolemia. <b>2000</b> , 36, 1483-8		70
93	Impaired renal vascular endothelial function in vitro in experimental hypercholesterolemia. <b>2001</b> , 154, 195-201		37
92	Endothelin receptor antagonists in congestive heart failure: a new therapeutic principle for the future?. <b>2001</b> , 37, 1493-505		121
91	Endothelin receptor antagonists and cardiovascular diseases of aging. <b>2001</b> , 18, 425-40		6
90	c-myc activation in early coronary lesions in experimental hypercholesterolemia. <b>2001</b> , 281, 945-50		24
89	Involvement of oxidation-sensitive mechanisms in the cardiovascular effects of hypercholesterolemia. <b>2001</b> , 76, 619-31		38
88	Therapeutic potential for endothelin receptor antagonists in cardiovascular disorders. <b>2001</b> , 1, 293-303		19
87	Blockade of endothelin receptors reduces diet-induced hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice. <b>2001</b> , 69, 1-10		15
86	Treatment with endothelin-receptor antagonists increases NOS activity in hypercholesterolemia. <b>2001</b> , 90, 816-20		24
85	New insight and therapeutic strategies in cardiovascular disease and focus on endothelial target: endothelin-1 and angina. <b>2001</b> , 38 Suppl 2, S27-30		4

84	Current strategies and perspectives for correcting endothelial dysfunction in atherosclerosis. <b>2001</b> , 38 Suppl 2, S35-41	17
83	Coronary vascular endothelial function and myocardial ischemia: why should we worry about endothelial dysfunction?. <b>2001</b> , 12, 475-84	11
82	Basic and therapeutic relevance of endothelin-mediated regulation. <b>2001</b> , 24, 1219-30	30
81	Involvement of Oxidation-Sensitive Mechanisms in the Cardiovascular Effects of Hypercholesterolemia. <b>2001</b> , 76, 619-631	64
80	Are selective endothelin A receptor antagonists better than mixed antagonists?. <b>2001</b> , 38 Suppl 2, S43-6	11
79	Gender-related differences in proliferative responses of vascular smooth muscle cells to endothelin-1. <b>2001</b> , 8, 137-45	15
78	Influence of nitric oxide synthase inhibition and endothelin-1 receptor blockade on acetylcholine-induced coronary artery contraction in vitro in dilated and ischemic cardiomyopathies. <b>2001</b> , 38, 90-8	18
77	The therapeutic potential of endothelin receptor antagonists in cardiovascular disease. <b>2001</b> , 3, 322-30	22
76	Crosstalk between endothelin and nitric oxide in the control of vascular tone. <b>2001</b> , 6, 265-76	57
75	Endothelin A receptor antagonists in congestive heart failure: blocking the beast while leaving the beauty untouched?. <b>2001</b> , 6, 301-15	16
74	Role of endothelin ET(A) receptor antagonism in the post-transplant renal response to angiotensin II in the rat. <b>2001</b> , 86, 365-72	10
73	Relationship between neointimal thickness and shear stress after Wallstent implantation in human coronary arteries. <i>Circulation</i> , <b>2001</b> , 103, 1740-5	16.7 272
72	Coronary vasodilation and improvement in endothelial dysfunction with endothelin ET(A) receptor blockade. <b>2001</b> , 89, 969-76	58
71	Role of endothelin in cardiovascular disease. <b>2002</b> , 3, 1-15	134
70	Endothelin receptor antagonists prevent parathyroid cell proliferation caused by hypocalcemia in rats. <b>2002</b> , 11, 411-5	4
69	Endothelin: what does it tell us about myocardial and endothelial dysfunction?. <b>2002</b> , 365-373	
68	The therapeutic potential of endothelin-1 receptor antagonists and endothelin-converting enzyme inhibitors on the cardiovascular system. <b>2002</b> , 11, 1537-52	10
67	Chronic endothelin receptor antagonism prevents coronary vasa vasorum neovascularization in experimental hypercholesterolemia. <b>2002</b> , 39, 1555-61	37

66	Endothelin-1 and atherosclerosis: potential complications associated with endothelin-receptor blockade. <b>2002</b> , 160, 297-304	58
65	Endothelial dysfunction, hypertension and atherosclerosis. A review of the effects of lacidipine. <b>2002</b> , 3, 311-23	9
64	Lipids and endothelium-dependent vasodilation--a review. <b>2002</b> , 37, 1-15	33
63	Endothelin-1 receptor blockade prevents renal injury in experimental hypercholesterolemia. <b>2003</b> , 64, 962-9	38
62	Endothelin type A receptor antagonism restores myocardial perfusion response to adenosine in experimental hypercholesterolemia. <b>2003</b> , 168, 367-73	9
61	The neurohormonal paradigm: have we gone too far?. <b>2003</b> , 41, 1458-9	8
60	Statin effects beyond lipid lowering--are they clinically relevant?. <b>2003</b> , 24, 225-48	360
59	Role of ET-1 in the regulation of coronary circulation. <b>2003</b> , 81, 570-7	16
58	Endothelin, hypercholesterolemia and atherosclerosis. <b>2003</b> , 14, 477-90	28
57	Sickle cell crisis and endothelin antagonists. <b>2003</b> , 26, 225-9	6
56	[New expansion of endothelin research: perspectives for clinical application of endothelin-receptor antagonists]. <b>2003</b> , 121, 91-101	1
55	Effects of endothelins on cardiac and vascular cells: new therapeutic target for the future?. <b>2004</b> , 2, 53-63	28
54	Endothelin receptor antagonist TAK-044 arrests and reverses the development of carbon tetrachloride induced cirrhosis in rats. <b>2004</b> , 53, 1010-9	28
53	Editorial quiz: GI Snapshot. <b>2004</b> , 53, 1019-1019	78
52	Repeated epicardial coronary artery endothelial injuries lead to a global spontaneous coronary artery spasm. <b>2004</b> , 15, 137-45	11
51	Decrease of endothelin receptor subtype ETB and release of COX-derived products contribute to endothelial dysfunction of porcine epicardial coronary arteries in left ventricular hypertrophy. <b>2005</b> , 45, 499-508	9
50	Factor VIIa stimulates endothelin-1 synthesis in TNF-primed endothelial cells by activation of protease-activated receptor 2. <b>2005</b> , 108, 255-63	17
49	Anti-atherogenic effects of the methanol extract of Sorbus cortex in atherogenic-diet rats. <b>2005</b> , 28, 1444-9	28

48	Endothelin-1 enhances oxidative stress, cell proliferation and reduces apoptosis in human umbilical vein endothelial cells: role of ETB receptor, NADPH oxidase and caveolin-1. <b>2005</b> , 145, 323-33	144
47	The effect of DA-8159, a novel PDE5 inhibitor, on erectile function in the rat model of hypercholesterolemic erectile dysfunction. <b>2005</b> , 17, 409-16	31
46	The relationship between shear stress and flow-mediated dilatation: implications for the assessment of endothelial function. <b>2005</b> , 568, 357-69	408
45	Effects of L-arginine on the endogenous angiogenic response in a model of hypercholesterolemia. <b>2005</b> , 138, 291-8	17
44	Endothelin-1, via ETA receptor and independently of transforming growth factor-beta, increases the connective tissue growth factor in vascular smooth muscle cells. <b>2005</b> , 97, 125-34	100
43	Responses to neither exogenous nor endogenous endothelin-1 are altered in patients with hypercholesterolemia. <b>2005</b> , 46, 2667-72	2
42	Bosentan preserves endothelial function in mice overexpressing APP. <b>2006</b> , 27, 446-50	21
41	Genetic variation in the endothelin system: do polymorphisms affect the therapeutic strategies?. <b>2006</b> , 1069, 34-50	15
40	Endothelin-a receptor blockade improves renal microvascular architecture and function in experimental hypercholesterolemia. <b>2006</b> , 17, 3394-403	36
39	Endothelin: beyond a vasoconstrictor. <i>Circulation</i> , <b>2006</b> , 113, 1156-8	16.7 23
38	Homocysteine-induced endothelin-1 release is dependent on hyperglycaemia and reactive oxygen species production in bovine aortic endothelial cells. <b>2006</b> , 43, 175-83	27
37	The endothelin system and its antagonism in chronic kidney disease. <b>2006</b> , 17, 943-55	184
36	The dynamic vasa vasorum. <b>2007</b> , 75, 649-58	161
35	Role of Vasa Vasorum in Arterial Disease: A Re-emerging Factor. <b>2007</b> , 3, 43-55	10
34	Mechanisms of ET-1-induced endothelial dysfunction. <b>2007</b> , 50, 621-8	106
33	Selective and mixed endothelin receptor antagonism in cardiovascular disease. <b>2007</b> , 28, 573-9	59
32	Endothelins in health and disease. <b>2007</b> , 18, 272-82	58
31	P-selectin-mediated adhesion impairs endothelium-dependent arteriolar dilation in hypercholesterolemic mice. <b>2007</b> , 292, H632-8	10

30	Parathyroid hormone is inversely related to endothelin-1 in patients on haemodialysis. <b>2008</b> , 13, 467-71	2
29	Role of endothelin-1 in clinical hypertension: 20 years on. <b>2008</b> , 52, 452-9	130
28	Endothelin-1, aging and hypertension. <b>2008</b> , 23, 350-5	42
27	Endothelin-1 induces connective tissue growth factor expression in cardiomyocytes. <b>2009</b> , 46, 352-9	43
26	Endothelin receptor antagonists as antihypertensives: the next frontier. <b>2009</b> , 7, 675-87	7
25	Endothelium-derived endothelin-1. <b>2010</b> , 459, 951-8	77
24	Short-term exercise training prevents micro- and macrovascular disease following coronary stenting. <b>2010</b> , 108, 1766-74	15
23	Long-term administration of endothelin receptor antagonist improves coronary endothelial function in patients with early atherosclerosis. <i>Circulation</i> , <b>2010</b> , 122, 958-66	16.7 106
22	Oxidants and Endothelial Dysfunction. <b>2010</b> , 243-274	4
21	Role of endothelin in the cardiovascular system. <b>2011</b> , 63, 463-72	78
20	The discovery of endothelium-dependent contraction: the legacy of Paul M. Vanhoutte. <b>2011</b> , 63, 455-62	26
19	Endothelin antagonism in patients with nondiabetic chronic kidney disease. <b>2011</b> , 172, 243-254	10
18	A mitochondrial permeability transition pore inhibitor improves renal outcomes after revascularization in experimental atherosclerotic renal artery stenosis. <b>2012</b> , 60, 1242-9	99
17	Nitric oxide-mediated endothelium-dependent vasodilation is impaired with borderline high-LDL cholesterol. <b>2012</b> , 5, 21-6	6
16	Elevated levels of plasma Big endothelin-1 and its relation to hypertension and skin lesions in individuals exposed to arsenic. <b>2012</b> , 259, 187-94	28
15	Long-term endothelin receptor antagonism attenuates coronary plaque progression in patients with early atherosclerosis. <b>2013</b> , 168, 1316-21	50
14	Endothelin in coronary artery disease and myocardial infarction. <b>2013</b> , 21, 249-56	53
13	Potential therapeutic role of phosphodiesterase type 5 inhibition in hypertension and chronic kidney disease. <b>2014</b> , 63, 5-11	28

12	Utility of C-terminal proendothelin in the early diagnosis and risk stratification of patients with suspected acute myocardial infarction. <b>2014</b> , 30, 195-203	7
11	Eugenosedin-A ameliorates hyperlipidemia-induced vascular endothelial dysfunction via inhibition of $\alpha$ -adrenoceptor/5-HT activity and NADPH oxidase expression. <b>2014</b> , 30, 116-24	9
10	Endothelin. <b>2016</b> , 68, 357-418	400
9	Therapeutic potential of endothelin receptor antagonism in kidney disease. <b>2016</b> , 310, R388-97	17
8	Endothelin 1 and endothelial dysfunction in children with idiopathic nephrotic syndrome. <b>2017</b> , 18, 36	4
7	Oxidants and Endothelial Dysfunction. <b>2018</b> , 252-281	1
6	Aprocitentan, A Dual Endothelin Receptor Antagonist Under Development for the Treatment of Resistant Hypertension. <b>2021</b> , 10, 397-406	4
5	Endothelin antagonists for hypertension and renal disease. <b>1999</b> , 8, 549-56	23
4	Oxidative stress may explain how hypertension is maintained by normal levels of angiotensin II. <b>2000</b> , 33, 653-60	17
3	Endothelium: Dysfunction and Repair. <b>2009</b> , 187-210	
2	Endothelin Receptor Antagonists in Cardiovascular Medicine: Challenges and Opportunities. <b>2012</b> , 231-259	
1	Coronary Artery Calcification. <b>2018</b> , 9-20	